Year: 2019

ORLANDO, Fla., Dec. 13, 2019 (GLOBE NEWSWIRE) — Nearly every person suffering from atopic dermatitis, more popularly known as “eczema,” knows just how difficult it can be to find effective remedies for his or her condition. Many prescription and over-the-counter treatments are not always consistent in providing relief, making new revolutionary improved topical medications a welcome addition to the narrow range of dermatological products dedicated to treating this difficult-to-cure ailment. Hoth Therapeutics, Inc. (NASDAQ:HOTH), is one such pharmaceutical company focused on providing eczema patients with a non corticosteriod therapeutic that actually helps treat eczema rather than just stop the itch.BioLexa – A Competitive Advantage Among Its Industry PeersDespite the relatively narrow regime of therapies for atopic dermatitis,...

Company AnnouncementCHMP issued positive opinion for DARZALEX® in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantFinal decision from European Commission expected in the coming monthsOpinion based on data from Phase III CASSIOPEIA studyCopenhagen, Denmark; December 13, 2019 – Genmab A/S (Nasdaq: GMAB) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending broadening the existing marketing authorization for DARZALEX® (daratumumab) in the European Union. The recommendation is for the use of DARZALEX in in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients...

COPENHAGEN, Denmark, December 13, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that it has received antitrust clearance in the U.S., Spain and Portugal of its planned acquisition of the two commercial vaccines, Rabipur®/RabAvert® and Encepur®, from GlaxoSmithKline plc (GSK), announced on October 21, 2019.With these clearances, and the recent approval from the Company’s shareholders of a rights issue to fund part of the acquisition, the transaction will now proceed towards closing, expected by December 31, 2019.For more information about the transaction, see company announcement no. 19/2019.About Bavarian NordicBavarian Nordic is a fully integrated biotechnology company focused on the development of innovative therapies against infectious diseases and cancer. Using our live virus vaccine platform technology, MVA-BN®,...

KØBENHAVN, Danmark, 13. december 2019 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har fået godkendelse af konkurrencemyndighederne i USA, Spanien og Portugal af det planlagte køb af de to kommercielle vacciner, Rabipur®/RabAvert® og Encepur® fra GlaxoSmithKline plc (GSK), som blev offentliggjort den 21. oktober 2019.Med disse godkendelser samt den nylige godkendelse fra selskabets aktionærer af en fortegningsemission, der skal finansiere dele af købet, vil transaktionen nu fortsætte mod endelig gennemførelse (closing), der forventes at finde sted senest den 31. december 2019.For yderligere informationer om transaktionen henvises til selskabsmeddelelse nr. 19/2019.Om Bavarian NordicBavarian Nordic er et fuldt integreret biotekselskab, der er fokuseret på udvikling af innovative vacciner mod infektionssygdomme og kræft....

Keskisuomalainen Oyj:n osakemäärien muutoksetKeskisuomalainen Oyj pörssitiedote 13.12.2019 klo 10.30Keskisuomalainen Oyj:n K-osakkeita on muunnettu A-osakkeiksi kolmen muuntovaatimuksen perusteella 9 956 kappaletta. Nämä osakkeet on merkitty kaupparekisteriin 13.12.2019. Kaupankäynti näillä osakkeilla alkaa 16.12.2019.Osakkeet jakaantuvat muunnon jälkeen seuraavasti:K-osakkeita 4 936 681 kappaletta ja 98 733 620 ääntäA-osakkeita 5 800 022 kappaletta ja 5 800 022 ääntäMuunto ei vaikuta osakkeiden kokonaismäärään, joka on 10 736 703 kappaletta eikä osakepääoman määrään, joka on 2 257 283,80 euroa. Osakkeiden kokonaisäänimäärä on 104 533 642 ääntä.Lisätietoja: Vesa-Pekka Kangaskorpi, toimitusjohtaja, Keskisuomalainen Oyj, puh: 050 68833Keskisuomalainen OyjVesa-Pekka Kangaskorpitoimitusjohtajawww.keskisuomalainen.com

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONSNB Private Equity Partners Publishes Quarterly Report and Re-stated October NAV13 December 2019NB Private Equity Partners Limited (“NBPE” or the “Company”), a closed-end private equity investment company, today releases its 30 September 2019 Quarterly Report and Re-stated October Net Asset Value (“NAV”). Key highlights and commentary are below and the complete report can be found on the Company’s website at www.nbprivateequitypartners.com.Key Highlights·Year to date NAV development:Within the Quarterly Report, 30 September 2019 NAV per Share of $18.77 (£15.23) increased $0.90 (£1.20) from $17.87 (£14.03) NAV per Share at 31 December 201830 September...

Panostaja Oyj                       Financial Statement Bulletin                        December 13, 2019 at 9.00 am.Panostaja Oyj’s Financial Statement Bulletin 1.11.2018-31.10.2019Active efforts to improve profitability – profit/loss encumbered by cost provisionsAugust 1, 2019-October 31, 2019 (3 months)Net sales increased in three of the eight segments. Net sales for the Group as a whole weakened by 6% to MEUR 49.7 (MEUR 52.8).EBIT improved in four of the eight segments. The entire Group’s EBIT improved from the reference period, standing at MEUR 1.5 (MEUR -0.1). The profit/loss for the reference period includes the goodwill impairment loss of the Helakeskus segment in the amount of MEUR 3.0.Grano’s net sales for the review period declined by 7% from the reference period in the previous year. EBIT totaled MEUR 1.8 (MEUR 2.6)....

’s-Hertogenbosch, the Netherlands, 13 December 2019On 23 December 2019, Van Lanschot Kempen will return the previously announced amount of €1.50 per Class A share in issue, totalling over €60 million, to its shareholders.Van Lanschot Kempen’s shareholders approved the return of capital at an extraordinary general meeting on 9 October 2019. On 11 December 2019, the legally prescribed two-month objection period expired. No objections were made, and subsequently the payment date for the capital return has been fixed on 23 December.Van Lanschot Kempen is able to make this capital return payment to its shareholders as a result of its strong capital position. This return of capital will take the total capital returned, in the form of both dividend payments and capital returns, to €330 million since 2016.Van Lanschot Kempen will continue to...

’s-Hertogenbosch, 13 december 2019Van Lanschot Kempen zal op 23 december 2019 het eerder aangekondigde bedrag van € 1,50 per geplaatst gewoon aandeel A aan haar aandeelhouders uitkeren (in totaal ruim € 60 miljoen).Aandeelhouders stemden in met deze kapitaalteruggave tijdens de buitengewone algemene vergadering op 9 oktober 2019. Op 11 december 2019 verstreek de wettelijke verzetstermijn van twee maanden. Er is geen verzet gedaan, waardoor de betaaldatum van de kapitaaluitkering is vastgesteld op 23 december.Dankzij de sterke kapitaalpositie kan Van Lanschot Kempen opnieuw een kapitaalteruggave doen aan aandeelhouders. Na deze kapitaaluitkering zal ruim € 330 miljoen, zowel in de vorm van dividenden als kapitaalteruggaven, aan aandeelhouders zijn uitgekeerd sinds 2016.Van Lanschot Kempen zal haar kapitaalbasis blijven optimaliseren, waarbij...